Xspray Pharma Ab Stock Fundamentals
| XSPRAY Stock | SEK 41.40 1.10 2.59% |
XSpray Pharma AB fundamentals help investors to digest information that contributes to XSpray Pharma's financial success or failures. It also enables traders to predict the movement of XSpray Stock. The fundamental analysis module provides a way to measure XSpray Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XSpray Pharma stock.
XSpray |
XSpray Pharma AB Company Shares Owned By Insiders Analysis
XSpray Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current XSpray Pharma Shares Owned By Insiders | 47.42 % |
Most of XSpray Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XSpray Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 47.42% of XSpray Pharma AB are shares owned by insiders. This is 212.38% higher than that of the Healthcare sector and 234.41% higher than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.
XSpray Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XSpray Pharma's current stock value. Our valuation model uses many indicators to compare XSpray Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XSpray Pharma competition to find correlations between indicators driving XSpray Pharma's intrinsic value. More Info.XSpray Pharma AB is rated second in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XSpray Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XSpray Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.XSpray Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XSpray Pharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XSpray Pharma could also be used in its relative valuation, which is a method of valuing XSpray Pharma by comparing valuation metrics of similar companies.XSpray Pharma is currently under evaluation in shares owned by insiders category among its peers.
XSpray Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (116.51) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 22.68 M | |||
| Shares Owned By Insiders | 47.42 % | |||
| Shares Owned By Institutions | 27.60 % | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 1,206 X | |||
| Gross Profit | 656 K | |||
| EBITDA | (87.82 M) | |||
| Net Income | (96.7 M) | |||
| Cash And Equivalents | 192.85 M | |||
| Cash Per Share | 12.79 X | |||
| Total Debt | 1.19 M | |||
| Debt To Equity | 2.80 % | |||
| Current Ratio | 26.45 X | |||
| Book Value Per Share | 24.95 X | |||
| Cash Flow From Operations | (51.61 M) | |||
| Earnings Per Share | (5.18) X | |||
| Target Price | 135.0 | |||
| Number Of Employees | 26 | |||
| Beta | 0.97 | |||
| Market Capitalization | 1.45 B | |||
| Total Asset | 622.9 M | |||
| Net Asset | 622.9 M |
About XSpray Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XSpray Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XSpray Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XSpray Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.